Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Nature

• Publication date

  2014-11-26

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nature14011PMID 25428504PMCID PMC4836193
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.

  2014cited by this paper
• MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

  2014cited by this paper
• Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers

  2014cited by this paper
• Oncology meets immunology: the cancer-immunity cycle.

  2013cited by this paper
• Innate and adaptive immune cells in the tumor microenvironment

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• Dietary gluten triggers concomitant activation of CD4+ and CD8+ αβ T cells and γδ T cells in celiac disease

  2013cited by this paper
• Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

  2013cited by this paper
• Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.

  2013cited by this paper
• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors.

  2012cited by this paper
• Different Adaptations of IgG Effector Function in Human and Nonhuman Primates and Implications for Therapeutic Antibody Treatment

  2012cited by this paper
• Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In Vivo

  2011cited by this paper
• The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo

  2011cited by this paper
• Cancer immunotherapy comes of age

  2011cited by this paper
• PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance.

  2010cited by this paper
• Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma.

  2008cited by this paper
• Rapid cloning of high-affinity human monoclonal antibodies against influenza virus

  2008cited by this paper
• Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

  2007cited by this paper
• PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

  2006cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

  1999cited by this paper
• Interferon–inducible T Cell Alpha Chemoattractant (I-TAC): A Novel Non-ELR CXC Chemokine with Potent Activity on Activated T Cells through Selective High Affinity Binding to CXCR3

  1998cited by this paper
• A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans

  1996cited by this paper

• Bifurcation Analysis of Cancer-Immunity Cycle

  2026cites this paper
• A 12-gene immune signature predicts prognosis and identifies KRT6B as a therapeutic target in lung adenocarcinoma

  2026cites this paper
• Targeting Fatty Acids in Liver Cancer: Molecular Insights and Drug Approaches.

  2026cites this paper
• Precision cytokine modulation to overcome tumor microenvironment-driven resistance to immune checkpoint blockade.

  2026cites this paper
• Prognostic Significance of C-PLAN Index in Patients Treated with Immunotherapy for Non-Small-Cell Lung Cancer

  2026cites this paper
• Dynamic reprogramming of the tumor immune network via multicycle checkpoint degradation for cancer immunotherapy.

  2026cites this paper
• Tumor microenvironment heterogeneity and immunotherapy resistance: multidimensional modulation strategies for precision breakthroughs

  2026cites this paper
• Do Metastatic Cells Arise from PD-L1+ Cell Niches in Gastric Adenocarcinoma?

  2026cites this paper
• ITGA8 suppresses proliferation and metastasis of lung adenocarcinoma through the inhibition of glycolysis.

  2026cites this paper
• Tumor-associated macrophages in head and neck carcinoma: clinicopathological correlations and implications for immunotherapy

  2026cites this paper
• First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial.

  2026cites this paper
• Immunometabolic heterogeneity in hepatocellular carcinoma: transforming cold tumors into hot tumors.

  2026cites this paper
• Charting cell-type-specific positive genetic interaction at single-cell resolution for lung adenocarcinoma.

  2026cites this paper
• Critical Insight into the Relationship and Dynamic Complexity of Pyroptosis and Inflammation in Cancer Microenvironment: Potential Multifaceted Intervention Points in Tumor Immunotherapy

  2026cites this paper
• Pre-Existing Immunity Shapes Cancer Immunotherapy Efficacy

  2026cites this paper
• A multi-omics features-based approach integrating immunogenicity and inflammation enhances immunotherapy benefit in clear cell renal cell carcinoma

  2026cites this paper
• Immunotherapy in Small Cell Lung Cancer: Advances, Barriers, and Emerging Strategies

  2026cites this paper
• Impact of adjuvant anti-PD-1 immunotherapy on ovarian function in female patients with resectable melanoma: A prospective observational study.

  2026cites this paper
• Comprehensive post-marketing safety evaluation of atezolizumab: A disproportionality analysis based on individual case safety reports in the FAERS.

  2026cites this paper
• Immunohistochemical Expression of Programmed Death-Ligand 1 Associated with Human Papillomavirus-Driven High-Grade Cervical Intraepithelial Neoplasia in South African Women

  2026cites this paper
• Disparities in Tumor Microenvironment Between Primary and Metastatic Colorectal Cancer: Impact on Immune Infiltration and Survival.

  2026cites this paper
• Inferring Phenotypes of Single Cells Based on the Expression Profiles of Phenotype-Associated Marker Genes in Bulks and Single Cells.

  2026cites this paper
• Integrative Spatial Omics and Artificial Intelligence: Transforming Cancer Research with Omics Data and AI.

  2026cites this paper
• Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2026cites this paper
• Disulfidptosis-based cancer therapy: Opportunity and challenge

  2026cites this paper
• CRISPR/Cas strategies to enhance CAR T-cell function and persistence via metabolic reprogramming.

  2026cites this paper
• Cemiplimab in the treatment of cutaneous squamous cell carcinoma.

  2026cites this paper
• Research Progress and Clinical Translation Challenges of Small‐Molecule Inhibitors Targeting PD‐L1

  2026cites this paper
• CSF proteomics identifies ADGRG1 as a predictive biomarker of intrathecal immune checkpoint inhibitor response in leptomeningeal metastasis

  2026cites this paper
• Integrated ICD-based subtyping and prognostic model reveal KCNN4 as a novel therapeutic target in NSCLC.

  2026cites this paper
• Efficacy and safety of immune checkpoint inhibitors and mTOR inhibitors as targeted therapy for glioblastoma: A systematic review and meta-analysis of randomized clinical trials

  2026cites this paper
• Chiral and Dual Drugs Combination Reduces Tumor-Associated Neutrophils-Induced T-Cell Immunoparalysis to Treat Epithelial Ovarian Cancer.

  2026cites this paper
• The clinical characteristics, mechanism and management of immune checkpoint inhibitor-related arthritis

  2026cites this paper
• Palmitic acid-triggered B7H3 palmitoylation promotes immune escape

  2026cites this paper
• Production and Characterization of Novel Murine Monoclonal Antibodies Against Programmed Death-Ligand 1 with Potential Diagnostic Application in Immunohistochemistry.

  2026cites this paper
• Reproductive Toxicity of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer: A Case Report with a Literature Review.

  2026cites this paper
• Prognostic value of PD-L1 expression on tumor-infiltrating immune cells and neutrophil-to-lymphocyte ratio in patients with biliary tract cancer.

  2026cites this paper
• Three Cases of Resection of Alpha-Fetoprotein-Positive High-Grade Fetal Adenocarcinoma of the Lung From a Single Institution.

  2026cites this paper
• Concordance Between the PD-L1 Tumor Area Positivity Score and Combined Positive Score for Gastric or Esophageal Cancers Treated With Tislelizumab.

  2025cites this paper
• Recent advances in biomarkers for predicting the efficacy of immunotherapy in non-small cell lung cancer

  2025cites this paper
• Predictive biomarkers in the era of immunotherapy for gastric cancer: current achievements and future perspectives

  2025cites this paper
• Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy Compared with Chemotherapy as First-Line Treatment for Advanced PD-L1-Positive Triple-Negative Breast Cancer from a Japanese Healthcare Perspective

  2025cites this paper
• Elevated HDAC4 Expression Is Associated with Reduced T-Cell Inflamed Tumor Microenvironment Gene Signatures and Immune Checkpoint Inhibitor Effectiveness in Melanoma

  2025cites this paper
• Overcoming the novel glycan-lectin checkpoints in tumor microenvironments for the success of the cross-presentation-based immunotherapy.

  2025cites this paper
• A novel model for predicting immunotherapy response and prognosis in NSCLC patients

  2025cites this paper
• Innovative Immunotherapy and Its Transformative Impact on Gastric Adenocarcinoma: A Comprehensive Review of the Disease's Origins, Epidemiology, Classification, Diagnosis, and Treatment Options.

  2025cites this paper
• An Ultrasound-based Machine Learning Model for Predicting Tumor-Infiltrating Lymphocytes in Breast Cancer

  2025cites this paper
• Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors

  2025cites this paper
• Exosomal PD-L1 in non-small cell lung Cancer: Implications for immune evasion and resistance to immunotherapy.

  2025cites this paper
• Multi-omic profiling in breast cancer: utility for advancing diagnostics and clinical care

  2025cites this paper
• Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysis

  2025cites this paper
• Combining spatial transcriptomics and ECM imaging in 3D for mapping cellular interactions in the tumor microenvironment.

  2025cites this paper
• Circular RNA CDYL facilitates hepatocellular carcinoma stemness and PD-L1+ exosomes-mediated immunotherapy resistance via stabilizing hornerin protein by blocking synoviolin 1-mediated ubiquitination.

  2025cites this paper
• Cost-Effectiveness Analysis of Enfortumab Vedotin plus Pembrolizumab as First-Line Treatment for Advanced Urothelial Carcinoma

  2025cites this paper
• Approaches to Imaging Immune Activation Using PET

  2025cites this paper
• Activating the CXCR3/CXCL10 pathway overrides tumor immune suppression by enhancing immune trafficking and effector cell priming in head and neck squamous cell carcinoma

  2025cites this paper
• Spatial analysis identifies DC niches as predictors of pembrolizumab therapy in head and neck squamous cell cancer

  2025cites this paper
• A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours

  2025cites this paper
• Phase 2 trial of imprime and pembrolizumab immunotherapy in metastatic triple negative breast cancer patients who have progressed beyond first line chemotherapy.

  2025cites this paper
• Exploring CISD1 as a multifaceted biomarker in cancer: Implications for diagnosis, prognosis, and immunotherapeutic response

  2025cites this paper
• Of Context, Quality, and Complexity: Fine-combing Tumor Mutation Burden in Immunotherapy Treated Cancers.

  2025cites this paper
• Harnessing the power of tumor-draining lymph nodes: unveiling predictive biomarkers for immune checkpoint inhibitor

  2025cites this paper
• Identification of Dinaciclib and Ganetespib as anti-inflammatory drugs using a novel HTP screening assay that targets IFNγ-dependent PD-L1

  2025cites this paper
• Hallmarks of terminal T-cell exhaustion are absent in multiple myeloma from diagnosis through maintenance therapy.

  2025cites this paper
• A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome

  2025cites this paper
• Abscopal Effects and Immunomodulation in Skin Cancer Therapy

  2025cites this paper
• Combating cancer immunotherapy resistance: a nano‐medicine perspective

  2025cites this paper
• T-bet+CD8+ T cells govern anti-PD-1 responses in microsatellite-stable gastric cancers

  2025cites this paper
• Novel Pt@PCN-Cu-induced cuproptosis amplifies αPD-L1 immunotherapy in pancreatic ductal adenocarcinoma through mitochondrial HK2-mediated PD-L1 upregulation

  2025cites this paper
• Monoclonal antibody immune therapy response instrument for stratification and cost-effective personalized approaches in 3PM-guided pan cancer management

  2025cites this paper
• Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.

  2025cites this paper
• A protease-cleavable liposome for co-delivery of anti-PD-L1 and doxorubicin for colon cancer therapy in mice

  2025cites this paper
• Development of Novel Short Peptide Inhibitor Targeted to Immune Checkpoint PD-1 LBD

  2025cites this paper
• Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy

  2025cites this paper
• CTLA-4—two pathways to anti-tumour immunity?

  2025cites this paper
• Non-invasive PD-L1 stratification in non-small cell lung cancer using dynamic contrast-enhanced MRI

  2025cites this paper
• Preclinical and first‑in‑human evaluation of [68Ga]Ga-DOTA-PEG2-Asp2-PDL1P PET imaging to assess tumor PD-L1 expression

  2025cites this paper
• Prospect of extracellular vesicles in tumor immunotherapy

  2025cites this paper
• High baseline levels of PD-L1 reduce the heterogeneity of immune checkpoint signature and sensitize anti-PD1 therapy in lung and colorectal cancers

  2025cites this paper
• Significance of CD8+T cells related gene ITGB2 in prognosis and tumor microenvironment of small cell lung cancer

  2025cites this paper
• Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back

  2025cites this paper
• Adverse drug reactions to atezolizumab in combination with bevacizumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database

  2025cites this paper
• Bioactive metallic nanoparticles for synergistic cancer immunotherapy

  2025cites this paper
• Molecular and immunological features associated with long-term benefits in metastatic NSCLC patients undergoing immune checkpoint blockade

  2025cites this paper
• Axillary lymph node metastasis in breast cancer: from historical axillary surgery to updated advances in the preoperative diagnosis and axillary management

  2025cites this paper
• Machine learning identifies clinical tumor mutation landscape pathways of resistance to checkpoint inhibitor therapy in NSCLC

  2025cites this paper
• Immuno-Activated, Highly Expressing PD-1 Phenotype in Hepatocellular Carcinoma Is Associated with a Lower Recurrence Rate

  2025cites this paper
• Exploring radiation resistance-related genes in pancreatic cancer and their impact on patient prognosis and treatment

  2025cites this paper
• Inherent PD‐L1 22C3 Expression in Alveolar Macrophages Impacts the Combined Positive Score Status in Breast Cancer With Pulmonary Metastasis

  2025cites this paper
• PRMT3 drives PD-L1-mediated immune escape through activating PDHK1-regulated glycolysis in hepatocellular carcinoma

  2025cites this paper
• Opportunities for Discovery Using Neoadjuvant Immune Checkpoint Blockade in Melanoma

  2025cites this paper
• Comparison analysis of ICIs and chemotherapy combined with or without lenvatinib as first-line treatment of unresectable intrahepatic cholangiocarcinoma

  2025cites this paper
• TERT promoter mutations or protein overexpression define an aggressive subset with favourable immunotherapeutic response in advanced urothelial carcinoma

  2025cites this paper
• Single-cell sequencing reveals tumor microenvironment features associated with the response to neoadjuvant immunochemotherapy in oral squamous cell carcinoma

  2025cites this paper
• Meta-Analysis of Safety and Efficacy of Atezolizumab plus Bevacizumab in Advanced Hepatocelluar Carcinoma

  2025cites this paper
• Immunotherapy benefits PD‑L1‑positive gastric‑type endocervical adenocarcinoma: A multicenter, retrospective study

  2025cites this paper
• Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy.

  2025cites this paper
• Immunogenomic precision medicine: a personalized approach based on immunogenomic cancer evolution.

  2025cites this paper
• Cutaneous melanoma

  2025cites this paper
• The Tight Relationship Between the Tumoral Microenvironment and Radium-223

  2025cites this paper